

Tim Dudderidge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10511883/publications.pdf>

Version: 2024-02-01

23
papers

2,000
citations

516710

16
h-index

610901

24
g-index

24
all docs

24
docs citations

24
times ranked

4743
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. <i>Nature Genetics</i> , 2013, 45, 385-391.	21.4	492
2	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. <i>Nature Genetics</i> , 2015, 47, 367-372.	21.4	380
3	A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. <i>European Urology</i> , 2018, 74, 422-429.	1.9	220
4	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. <i>Nature Genetics</i> , 2018, 50, 682-692.	21.4	182
5	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. <i>European Urology</i> , 2019, 76, 831-842.	1.9	148
6	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. <i>Human Molecular Genetics</i> , 2013, 22, 408-415.	2.9	118
7	Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. <i>European Urology</i> , 2019, 76, 98-105.	1.9	96
8	Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. <i>Health Technology Assessment</i> , 2018, 22, 1-176.	2.8	70
9	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. <i>Lancet Oncology</i> , The, 2021, 22, 1618-1631.	10.7	48
10	Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. <i>European Urology</i> , 2022, 81, 407-413.	1.9	41
11	Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. <i>PLoS Genetics</i> , 2017, 13, e1007001.	3.5	34
12	Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 567-574.	3.9	28
13	Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry. <i>BJU International</i> , 2020, 125, 853-860.	2.5	23
14	Focal HIFU therapy for anterior compared to posterior prostate cancer lesions. <i>World Journal of Urology</i> , 2021, 39, 1115-1119.	2.2	23
15	Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): A prospective, multi-centre therapeutic phase II parallel Randomised Control Trial. <i>Contemporary Clinical Trials</i> , 2020, 93, 105999.	1.8	20
16	Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer. <i>BJU International</i> , 2018, 122, 970-977.	2.5	17
17	Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e042953.	1.9	15
18	Assessment of Return to Baseline Urinary and Sexual Function Following Primary Focal Cryotherapy for Nonmetastatic Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 301-308.	3.1	11

#	ARTICLE	IF	CITATIONS
19	Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control. Prostate Cancer and Prostatic Diseases, 2021, 24, 1120-1128.	3.9	10
20	An Exploratory Study of Dose Escalation <i>vs</i> Standard Focal High-Intensity Focused Ultrasound for Treating Nonmetastatic Prostate Cancer. Journal of Endourology, 2020, 34, 641-646.	2.1	7
21	Focal therapy, time to join the multi-disciplinary team discussion?. Translational Andrology and Urology, 2020, 9, 1526-1534.	1.4	4
22	PD56-08 THE PART TRIAL - A PHASE III STUDY COMPARING PARTIAL PROSTATE ABLATION VERSUS RADICAL PROSTATECTOMY (PART) IN INTERMEDIATE RISK PROSTATE CANCER – EARLY DATA FROM THE FEASIBILITY STUDY. Journal of Urology, 2017, 197, .	0.4	3
23	High-intensity focused ultrasound focal therapy for prostate cancer. Trends in Urology & Men's Health, 2020, 11, 15-18.	0.4	1